Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 10Thoracic 1Plasma cell 1Myeloid 1Gynecologic 1Breast 1

Conditions

Endometrial Neoplasms 2Stomach Neoplasms 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Multiple Myeloma 1Lung Neoplasms 1Cholangiocarcinoma 1Breast Neoplasms 1

Interventions

pembrolizumab 13Nivolumab 6Gemcitabine 5Paclitaxel 4Cisplatin 4Magnetic Resonance Spectroscopy 3Ipilimumab 3Fluorouracil 3Fluorodeoxyglucose F18 3Carboplatin 3spartalizumab 2fludarabine 2budigalimab 2Oxaliplatin 2Leucovorin 2Irinotecan 2FAPI-46 2Drug Therapy 2Docetaxel 2Cyclophosphamide 2Bevacizumab 2venetoclax 1ulixertinib 1tislelizumab 1seribantumab 1saracatinib 1rovalpituzumab tesirine 1pertuzumab 1pemigatinib 1nilotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cholangiocarcinoma × pemigatinib × Gynecologic × Clear all
NCT02393248 2023-01-06

Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)

Incyte Corporation

Phase 1/2 Terminated
201 enrolled 71 charts
BreastGastrointestinalGynecologicMyeloidPlasma cellThoracic

Breast Neoplasms, Lung Neoplasms, Multiple Myeloma, Myeloproliferative Disorders, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡